Search

Your search keyword '"Rebecca Ronsley"' showing total 3 results
Start Over Author "Rebecca Ronsley" Publisher elsevier
3 results on '"Rebecca Ronsley"'

1. Locoregional CAR T cells for children with CNS tumors: Clinical procedure and catheter safety

Author

Nicholas A. Vitanza, Rebecca Ronsley, Michelle Choe, Casey Henson, Mandy Breedt, Adriel Barrios-Anderson, Amy Wein, Christopher Brown, Adam Beebe, Ada Kong, Danielle Kirkey, Brittany M. Lee, Sarah E.S. Leary, Erin E. Crotty, Corrine Hoeppner, Susan Holtzclaw, Ashley L. Wilson, Joshua A. Gustafson, Jessica B. Foster, Jeffrey J. Iliff, Hannah E. Goldstein, Samuel R. Browd, Amy Lee, Jeffrey G. Ojemann, Navin Pinto, Juliane Gust, Rebecca A. Gardner, Michael C. Jensen, Jason S. Hauptman, and Julie R. Park

Subjects
Chimeric antigen receptor (CAR) T cells, Central nervous system (CNS) tumor, Ommaya, CNS catheter, Ventriculoperitoneal (VP) shunt, HER2, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282
Abstract

Central nervous system (CNS) tumors are the most common solid malignancy in the pediatric population. Based on adoptive cellular therapy's clinical success against childhood leukemia and the preclinical efficacy against pediatric CNS tumors, chimeric antigen receptor (CAR) T cells offer hope of improving outcomes for recurrent tumors and universally fatal diseases such as diffuse intrinsic pontine glioma (DIPG). However, a major obstacle for tumors of the brain and spine is ineffective T cell chemotaxis to disease sites. Locoregional CAR T cell delivery via infusion through an intracranial catheter is currently under study in multiple early phase clinical trials. Here, we describe the Seattle Children's single-institution experience including the multidisciplinary process for the preparation of successful, repetitive intracranial T cell infusion for children and the catheter-related safety of our 307 intracranial CAR T cell doses.

Published
2023
Full Text
View/download PDF

2. Ensuring the Safety of Children Treated with Second-Generation Antipsychotics

Author

Kristine D. Kuss, Jana Davidson, Rebecca Ronsley, Lorrie Chow, and Constadina Panagiotopoulos

Subjects
medicine.medical_specialty, Pediatrics, business.industry, medicine.medical_treatment, medicine.disease, Effective dose (pharmacology), Obesity, Impaired glucose tolerance, medicine, Medical prescription, Metabolic syndrome, Psychiatry, Antipsychotic, business, Dyslipidemia
Abstract

Second-generation antipsychotic (SGA) prescriptions for children have steadily increased over the past two decades. This is in part due to the perception of a reduction in neurological side effects with SGAs as compared to first-generation antipsychotics. However, the current literature shows that children treated with SGAs are at risk for metabolic side effects including central obesity, impaired glucose tolerance, hypertension, dyslipidemia, and metabolic syndrome. To ensure the safety of children treated with SGAs, it is important that (1) these medications are used for evidence-based indications only; (2) prescribing physicians monitor metabolic changes at regular time intervals per the current recommendations; and (3) metabolic complications are identified early and treated through promotion of a healthy lifestyle, use of the lowest effective dose of the SGA, and reduction in the use of multiple medications.

Published
2015
Full Text
View/download PDF

3. Contributors

Author

Mai Berger, Bruce Carleton, Lorrie Chow, Jana Davidson, Nina Di Pietro, Dean Elbe, David Gardner, Judy Illes, Osman Ipsiroglu, Kristine Kuss, Stan Kutcher, Tami Lin, Edel Mc Glanaghy, Andrea Murphy, Tim F. Oberlander, Iliana Garcia Ortega, Constadina Panagiotopoulos, Tamara Pringsheim, Rebecca Ronsley, Sylvia Stockler, and Benjamin Wilfond

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results